The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, July 12, 2016, Arthritis Advisory Committee (AAC) meeting to discuss biologics license application(BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.'s Humira (adalimumab), submitted by Amgen, Inc. (Amgen).
See the SAC Tracker report